Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-(3,4'-bipyridin)-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2h-cyclopenta(4,5)pyrrolo(1,2-a)pyrazin-1(6h)-one
2. Gdc-0853
1. Gdc-0853
2. 1434048-34-6
3. Rg7845
4. Gdc0853
5. Rg-7845
6. Fenebrutinib [inn]
7. Fenebrutinib [usan]
8. Ro7010939
9. E9l2885wul
10. (s)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6h)-one
11. Chembl4065122
12. G02599853
13. Ro-7010939
14. G-02599853
15. 10-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-9-one
16. 2-[3'-(hydroxymethyl)-1-methyl-5-({5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo[1,6-dihydro[3,4'-bipyridine]]-2'-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6h)-one
17. Fenebrutinib (usan/inn)
18. Fenebrutinib [usan:inn]
19. Unii-e9l2885wul
20. Fenebrutinib (gdc-0853)
21. Fenebrutinib [who-dd]
22. Gtpl9299
23. Schembl14912882
24. Bcp19175
25. Ex-a1308
26. Gdc 0853
27. Gdc-0853gdc-0853
28. Bdbm50244440
29. Nsc798202
30. S8421
31. Zinc220197997
32. Cs-5927
33. Db14785
34. Gdc-0853(rg7845)
35. Nsc-798202
36. Ac-32585
37. Bs-15120
38. Hy-19834
39. Rg-7845 (gdc-0853)
40. Example 130 [us20140194408]
41. J3.615.209e
42. A16339
43. D11457
44. A904370
45. Q23304817
46. (s)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl- 4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-(3,4'-bipyridin)-2'-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1h-cyclopenta (4,5)pyrrolo(1,2-a)pyrazin-1-one
47. 2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-(3,4'-bipyridin)-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2h-cyclopenta(4,5)pyrrolo(1,2-a)pyrazin-1(6h)-one
48. 2h-cyclopenta(4,5)pyrrolo(1,2-a)pyrazin-1(6h)-one, 2-(1,6-dihydro-3'-(hydroxymethyl)-1-methyl-5-((5-((2s)-2-methyl-4-(3-oxetanyl)-1-piperazinyl)-2-pyridinyl)amino)-6-oxo(3,4'-bipyridin)-2'-yl)-3,4,7,8-tetrahydro-7,7-dimethyl-
49. 2h-cyclopenta(4,5)pyrrolo(1,2-a)pyrazin-1(6h)-one, 2-(1,6-dihydro-3'-(hydroxymethyl)-1-methyl-5-((5-((2s)-2-methyl-4-(3-oxetanyl)-1-piperazinyl)-2-pyridinyl)amino)-6-oxo(3,4'-bipyridin)-2'-yl)3,4,7,8-tetrahydro-7,7-dimethyl-
50. 9aj
| Molecular Weight | 664.8 g/mol |
|---|---|
| Molecular Formula | C37H44N8O4 |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 664.34855191 g/mol |
| Monoisotopic Mass | 664.34855191 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 49 |
| Formal Charge | 0 |
| Complexity | 1340 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of multiple sclerosis
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Fenebrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fenebrutinib, including repackagers and relabelers. The FDA regulates Fenebrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fenebrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fenebrutinib supplier is an individual or a company that provides Fenebrutinib active pharmaceutical ingredient (API) or Fenebrutinib finished formulations upon request. The Fenebrutinib suppliers may include Fenebrutinib API manufacturers, exporters, distributors and traders.
Fenebrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fenebrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fenebrutinib GMP manufacturer or Fenebrutinib GMP API supplier for your needs.
A Fenebrutinib CoA (Certificate of Analysis) is a formal document that attests to Fenebrutinib's compliance with Fenebrutinib specifications and serves as a tool for batch-level quality control.
Fenebrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Fenebrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fenebrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Fenebrutinib EP), Fenebrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fenebrutinib USP).
LOOKING FOR A SUPPLIER?
